Novel Thiazolidine-2,4-dione-trimethoxybenzene-thiazole Hybrids as Human Topoisomerases Inhibitors

Cancer is a complex and heterogeneous disease and is still one of the leading causes of morbidity and mortality worldwide, mostly as the population ages. Despite the encouraging advances made over the years in chemotherapy, the development of new compounds for cancer treatments is an urgent priority...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceuticals (Basel, Switzerland) Switzerland), 2023-06, Vol.16 (7), p.946
Main Authors: Sinicropi, Maria Stefania, Ceramella, Jessica, Vanelle, Patrice, Iacopetta, Domenico, Rosano, Camillo, Khoumeri, Omar, Abdelmohsen, Shawkat, Abdelhady, Wafaa, El-Kashef, Hussein
Format: Article
Language:English
Subjects:
anticancer activity
Antimitotic agents
Antineoplastic agents
Breast cancer
Chemical properties
Chemical Sciences
human topoisomerases inhibition
hybrid drug design
Hydrogen bonds
Investigations
Kinases
Potassium
Proteins
Signal transduction
Simulation
Testing
thiazole
thiazolidinedione
trimethoxybenzene
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cancer is a complex and heterogeneous disease and is still one of the leading causes of morbidity and mortality worldwide, mostly as the population ages. Despite the encouraging advances made over the years in chemotherapy, the development of new compounds for cancer treatments is an urgent priority. In recent years, the design and chemical synthesis of several innovative hybrid molecules, which bring different pharmacophores on the same scaffold, have attracted the interest of many researchers. Following this strategy, we designed and synthetized a series of new hybrid compounds that contain three pharmacophores, namely trimethoxybenzene, thiazolidinedione and thiazole, and tested their anticancer properties on two breast cancer (MCF-7 and MDA-MB-231) cell lines and one melanoma (A2058) cell line. The most active compounds were particularly effective against the MCF-7 cells and did not affect the viability of the normal MCF-10A cells. Docking simulations indicated the human Topoisomerases I and II (hTopos I and II) as possible targets of these compounds, the inhibitory activity of which was demonstrated by the mean of direct enzymatic assays. Particularly, compound was proved to inhibit both the hTopo I and II, whereas compounds blocked only the hTopo II. Finally, compound was responsible for MCF-7 cell death by apoptosis. The reported results are promising for the further design and synthesis of other analogues potentially active as anticancer tools.
ISSN:1424-8247
1424-8247
DOI:10.3390/ph16070946